“Therapeutic reprogramming of pancreatic cancer stroma via modulation of p62 and p53”

Principal Investigators:
Andrew Lowy, MD (Moores Cancer Center)
Geoffrey M. Wahl, PhD (Salk)
Cosimo Commissio, PhD (Sanford Burnham Prebys)
Jorge Moscat, PhD (Sanford Burnham Prebys)

Abstract:
Pancreatic cancer remains the most deadly common cancer in the U.S. with a five-year survival rate of 6 percent. Despite the fact that fewer persons are diagnosed with pancreatic cancer than many other cancers, this high death rate will likely make it the No. 2 cancer killer by 2020. Researchers have identified that the non-cancerous cells present in pancreatic tumors have lost the function of two critical proteins that normally act to suppress cancer development. This grant will allow new tools to be developed by researchers to rapidly screen through a very large number of drugs in order to identify those which can restore the function of these proteins. By identifying such drugs, they can then be tested as part of a new treatment approach to pancreatic cancer.